Evidence map›Paper›PMID 32519518›Full record

ArticleCancer medicine2020

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.

Yizhen Liu, Kai Xue, Zuguang Xia, Jia Jin, Jiachen Wang, Hui Sun, Fangfang Lv, Xiaojian Liu, Junning Cao, Xiaonan Hong and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01667302 (A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01667302 phase2unknown statusnot on this map

A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma

TypeinterventionalSponsorFudan UniversityRan2012 to 2016Enrolled30ConditionsExtranodal NK/T-cell Lymphoma, Nasal TypeArmsRadiotherapy followed by chemotherapy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yizhen LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0002-1320-7364
Kai XueDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zuguang XiaDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jia JinDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiachen WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hui SunDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Fangfang LvDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaojian LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Junning CaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaonan HongDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ye GuoDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Xuejun MaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qunling ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal treatment strategies for extranodal natural killer/ T-cell lymphoma (ENKTL) have not been defined. We conducted this prospective, open-label, phase II, single-center study aimed to explore the efficacy and safety of radiotherapy followed by DICEP (Dexamethasone, ifosfamide, cisplatin, etoposide, and pegaspargase) regimen in the treatment of patients with untreated, stage IE/IIE, extranodal NK/T-cell lymphoma.

methodsThirty eligible patients were enrolled in this study, receiving radiotherapy of 50Gy/25fx, and followed by chemotherapy with DICEP regimen for 3 cycles if tolerated. Median follow-up time of this study was 70.8 months. We constructed Kaplan-Meier survival curves for survival analyses.

resultsThe most common manifestations at the onset of disease were nasal obstruction (80%), with or without fever, and pharyngalgia (20%). The overall response rate (ORR) was 96.7% (29/30). Four patients (13.3%) had progression of the disease (PD), the estimated 5-year progression-free survival (PFS) rate was 86%. Four patients (13.3%) died of disease, and the estimated 5-year cumulative overall survival (OS) was 87%. The most common hematological toxicity was grade 3 or grade 4 neutropenia, which could be successfully managed via using growth-stimulating factors or dose modifications. Hypoalbuminemia and decreased fibrinogen are the top two nonhematologic toxicities. No treatment-related death occurred in this study.

conclusionsOur present study showed that radiotherapy followed by DICEP chemotherapy could be an effective and tolerable treatment modality for newly diagnosed, stage IE/IIE ENKTL patients. Adverse events were predictable and manageable.

trial registrationClinicalTrials.gov Identifier: NCT01667302. Registered: 1 July 2012.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyCyclophosphamideEtoposideFemaleHumansLymphoma, Extranodal NK-T-CellMaleMiddle AgedNeoplasm StagingProgression-Free SurvivalSurvival AnalysisTreatment OutcomeCisplatinCyclophosphamideEtoposideDICENK/T-cell lymphomaPegaspargaseradiation

Identifiers

PMID32519518
PMCPMC7402823
OpenAlexW3033103962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.